ArticleInternational journal of vascular medicine2010
Mesoglycan: clinical evidences for use in vascular diseases.
Article in International journal of vascular medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02254850 (The Mesoglycan and Vascular Reactivity in the Metabolic Syndrome), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Mesoglycan and Vascular Reactivity in the Metabolic Syndrome
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Strategies to Reduce Post-Hemorrhoidectomy Pain: A Systematic Review.Medicina (Kaunas, Lithuania) · 2022Pooled it
- Evaluation of the Effects of Mesoglycan on Some Markers of Endothelial Damage and Walking Distance in Diabetic Patients with Peripheral Arterial Disease.International journal of molecular sciences · 2017Trial
- Mesoglycan for long-term secondary prevention in patients with superficial vein thrombosis (METRO): a multicentre randomised clinical trial in Italy.EClinicalMedicine · 2026Article
- Preclinical Evidence That Mesoglycan Unfolds Complex Anti-Aging Effects in Photoaged Female Facial Skin.International journal of molecular sciences · 2025Article
- Article
- Clinical evidence and rationale of mesoglycan to treat chronic venous disease and hemorrhoidal disease: a narrative review.Updates in surgery · 2024Review
- Mesoglycan for the secondary prevention of superficial vein thrombosis: a randomized, controlled, double-blind study (METRO Study)-rationale and protocol.Journal of thrombosis and thrombolysis · 2024Article
- Article
- Xioglican Cream in Italian Patients with Chronic Venous Disease: A Post-Marketing Study Investigating Effects on Clinical and Cutaneous Signs and Symptoms.Advances in therapy · 2023Observational
- Delphi case: Sharing of clinical experiences for improvement in the treatment of chronic venous disease.Frontiers in cardiovascular medicine · 2022Article
- Sudden Sensorineural Hearing Loss in Mild COVID-19: Case Series and Analysis of the Literature.Audiology research · 2021Article
- Oral administration of dermatan sulphate reduces venous thrombus formation in vivo: potential use as a formulation for venous thromboembolism.Inflammopharmacology · 2021Article
- PCL/Mesoglycan Devices Obtained by Supercritical Foaming and Impregnation.Pharmaceutics · 2019Article
- Effects of Prisma® Skin dermal regeneration device containing glycosaminoglycans on human keratinocytes and fibroblasts.Cell adhesion & migration · 2018Article
- Efficacy of Mesoglycan in Pain Control after Excisional Hemorrhoidectomy: A Pilot Comparative Prospective Multicenter Study.Gastroenterology research and practice · 2018Article
- The Pharmaceutical Device PrismaInternational journal of molecular sciences · 2017Article
- Mesoglycan attenuates VSMC proliferation through activation of AMP-activated protein kinase and mTOR.Clinical hypertension · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular glycosaminoglycans (GAG) are essential components of the endothelium and vessel wall and have been shown to be involved in several biologic functions. Mesoglycan, a natural GAG preparation, is a polysaccharide complex rich in sulphur radicals with strong negative electric charge. It is extracted from porcine intestinal mucosa and is composed of heparan sulfate, dermatan sulfate, electrophoretically slow-moving heparin, and variable and minimal quantities of chondroitin sulfate. Data on antithrombotic and profibrinolytic activities of the drug show that mesoglycan, although not indicated in the treatment of acute arterial or venous thrombosis because of the low antithrombotic effect, may be useful in the management of vascular diseases, when combined with antithrombotics in the case of disease of cerebral vasculature, and with antithrombotics and vasodilator drugs in the case of chronic peripheral arterial disease. The protective effect of mesoglycan in patients with venous thrombosis and the absence of side effects, support the use of GAG in patients with chronic venous insufficiency and persistent venous ulcers, in association with compression therapy (zinc bandages, multiple layer bandages, etc.), elastic compression stockings, and local care, and in the prevention of recurrences in patients with previous DVT following the standard course of oral anticoagulation treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.